0.20Open0.20Pre Close0 Volume530 Open Interest1.00Strike Price0.00Turnover165.16%IV2.44%PremiumAug 16, 2024Expiry Date0.18Intrinsic Value100Multiplier6DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.7800Delta1.6198Gamma4.10Leverage Ratio-0.0040Theta-0.0001Rho-3.20Eff Leverage0.0003Vega
Chimerix Stock Discussion
Phase I dose escalation trials continue at the National Institutes of Health (NIH) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) in adult and pediatric CNS tumor patients, respectively. The dose escalation trials are currently dosing at a...
This is all I need to hold and/or buy more on dips
"..Turning to clinical outcomes. The survival of H3 K27-mutant glioma patients who received ONC201 in the frontline setting following radiotherapy, which I'll notice the same setting of the ACTION trial was reported as 21.7 months from diagnosis in contrast to 12 months for patients who did not receive ONC201. Favorable survival outcomes among ONC201 treated patients were consistently observed across a variety of sensitivity ...
FIRST SIGNED OF MORE UPTREND: $2.64
NEED IT TO BREAK OVER: $2.75
key indicator for MORE uptrend $2.87
confirmation uptrend - $2.96
mini breakout - $3.01. $Chimerix (CMRX.US)$
No comment yet